>> BVF took some cash off the table and is still sitting on shares and warrants. <<
As of the most recent SEC filing, The Biotechnology Value Fund had sold about 85% of its original allotment of 3M GENR shares, but still held all of its 1.2M warrants (exercisable at $1.37).
BVF ought to consider changing the firm’s name because it is not really a “value” investor according to the conventional meaning of the term.
Market Data 
Markets 
AI
